SpringerLink
Log in

Zielgerichtete Therapie bei soliden Tumoren und in der Hämatoonkologie

Fortschritte und Enttäuschungen

Targeted therapy in the treatment of solid tumors and in hematology-oncology

Advances and disappointments

  • Arzneimitteltherapie
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Die Entwicklung und klinische Einführung zielgerichteter Therapien („targeted therapies“) ist ein wesentlicher Fortschritt in der Behandlung maligner Erkrankungen. Diese Therapieformen ergänzen die traditionellen Modalitäten Chemotherapie, Strahlentherapie und Chirurgie. Mit den neuen Therapieverfahren nimmt zum einen die Komplexität der Behandlungsmöglichkeiten in der Onkologie zu, zum anderen steigen die Therapiekosten. Parameter zu identifizieren, die eine Vorhersage hinsichtlich des Ansprechens auf die neuen Substanzen ermöglichen, ist ein wichtiger Gegenstand laufender Untersuchungen.

Abstract

The development and clinical introduction of targeted therapies has resulted in significant progress for the treatment of malignant diseases. These forms of therapy supplement traditional methods of chemotherapy, radiation, and surgery. As new therapies increase the complexity of therapeutic options in oncology, the treatment costs steadily climb as well. Parameters need to be identified which will predict a response to new substances, and this effort is the subject of ongoing studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1a, b
Abb. 2
Abb. 3

Literatur

  1. Berger U, Engelich G, Reiter A et al. (2004) Imatinib and beyond – the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia. Ann Hematol 83: 258–264

    Article  PubMed  Google Scholar 

  2. Blay JY, Bonvalot S, Casali P et al. (2005) Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 16: 566–578

    Article  PubMed  Google Scholar 

  3. Bonner JA, Harari PM, Giralt J et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578

    Article  Google Scholar 

  4. Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 22(351): 337–345

    Article  Google Scholar 

  5. Demetri GD, van Oosterom AT, Blackstein M et al. (2005) Phase III, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. J Clin Oncol 23, ASCO-Abstr. No 4000

  6. Dimopoulos MA (2005) Blood (ASH Annual Meeting Abstracts) 106: Abstract 6

  7. Escudier B, Szczylik C, Eisen T et al. (2005) Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer 3: 226, Abstract

    Google Scholar 

  8. Giantonio BJ, Catalano PJ, Meropol NJ et al. (2005) High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO 23

  9. Glasmacher A, Hahn C, Hoffmann F et al. (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132: 584–593

    Article  PubMed  Google Scholar 

  10. Hainsworth JD, Sosman JA, Spigel DR et al. (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23: 7889–7896

    Article  PubMed  Google Scholar 

  11. Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan,fluorouracil, and leucoverin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342

    Article  Google Scholar 

  12. Jagannath S (2004) A phase 2 study of two doses of bortezomib in relapsed or refratory myeloma. Br J Haematol 127: 165–172

    Article  PubMed  Google Scholar 

  13. Miller KD (2003) E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3: 421–432

    PubMed  Google Scholar 

  14. Moehler T, Neben K, Benner A et al. (2001) Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 98: 3846–3848

    Article  PubMed  Google Scholar 

  15. Moore MJ, Goldstein D, Hamm J et. al. (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clincal Trials Group [NCIC-CTG]. J Clin Oncol 23, ASCO-Abstr. No 1

  16. Motzer RJ, Michaelson MD, Redman BG et al. (2005) SU11248,a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, demonstrated antitumor activity in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 1–8

    PubMed  Google Scholar 

  17. O’Brien SG, Guilhot F, Larson RA et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994–1004

    Article  PubMed  Google Scholar 

  18. Pao W, Miller V, Zakowski M et al. (2004) EGF receptor gene mutations are common in lung cancers from „nevers smokers“ and are associated with sensivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 101: 13306–13311

    Article  PubMed  Google Scholar 

  19. Pfister DG, Su YB, Kraus DH et al. (2006) Concurrent Cetuximab, Cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24: 1072–1078

    Article  Google Scholar 

  20. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–1672

    Article  Google Scholar 

  21. Richardson PG, Sonneveld P, Schuster M.W et al. (2005) Bortezomib or high-dose Dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487–2498

    Article  PubMed  Google Scholar 

  22. Sandler AB, Gray R, Brahmer J et al. (2005) Randomized phase II/III-trial of Paclitaxel+Carboplatin with or without Bevacizumab in patients with advanced non-squamous non-small-cell lung cancer: An Eastern Cooperative Oncology Group trial – E4599. Proc Am Soc Clin Oncol 16: 2

    Google Scholar 

  23. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132

    Article  PubMed  Google Scholar 

  24. Tsao MS, Sakurada A, Cutz JC et al. (2005) Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med 353: 133–144

    Article  PubMed  Google Scholar 

  25. Yang JC, Haworth L, Sherry RM et al. (2003) A randomised trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434

    Article  Google Scholar 

  26. Zalcberg JR, Verweij J, Casali PG et al. (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41: 1751–1757

    Article  PubMed  Google Scholar 

  27. Zavrski I, Jakob C, Fleissner C et al. (2003) Proteasom-Inhibitoren. Onkologe 9: 1102–1107

    Article  Google Scholar 

  28. Daniel PT, Dörken B (2005) Grundlagen der molekularen Diagnostik und Therapie maligner Tumoren. Internist 46: 835–846

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Nationales Centrum für Tumorerkrankungen, Im Neuenheimer Feld 350, 69120 , Heidelberg

    C. Jochims, U. Mazitschek, D. Jäger &  H. Goldschmidt

  2. Medizinische Klinik V, Universitätsklinikum Heidelberg

    U. Mazitschek &  H. Goldschmidt

Authors
  1. C. Jochims
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Mazitschek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Jäger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Goldschmidt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jochims, C., Mazitschek, U., Jäger, D. et al. Zielgerichtete Therapie bei soliden Tumoren und in der Hämatoonkologie. Internist 47, 633–641 (2006). https://doi.org/10.1007/s00108-006-1626-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-006-1626-7

Schlüsselwörter

Keywords

Search

Navigation